5

<u>WE CLAIM:</u>

1. A method of treatment of dementia and/or regression of cognitive function, comprising the co-administration of effective amounts of an ANG II antagonist and

10 an ACE inhibitor to a person in need of such treatment.

2. The method of claim 1, wherein the ACE inhibitor is selected from the list consisting of benazepril, captopril, ceronapril, enalapril, fosinopril, imidapril, lisinopril, moexipril, quinapril, ramipril, trandolapril and perindopril.

15

3. The method of claim 1, wherein the ANG II antagonist is a sartan.

4. The method of claim 1, wherein the ACE inhibitor is administered in a daily dosage of 0.018 mg/kg to 6.429 mg/kg orally or of about 0.286 mg/kg parenterally

20 and the ANG II antagonist is administered in a daily dosage of 0.143 mg/kg to 7.143 mg/kg orally or of about 0.286 mg/kg parenterally.

5. The method of claim 4, wherein the ACE inhibitor is administered in a daily dosage of 0.071 mg/kg to 1.429 mg/kg orally and the ANG II antagonist is

25 administered in a daily dosage of 0.286 mg/kg to 1.429 mg/kg.

6. The method of claim 1, wherein the ACE inhibitor is administered in a daily dosage of 0.036 mg/kg to 0.143 mg/kg orally and the ANG II antagonist is administered in a daily dosage of 0.571 mg/kg to 1.143 mg/kg.

30

7. The method of claim 1, wherein the ACE inhibitor is ramipril and the ANG II antagonist is telmisartan.

8. Pharmaceutical composition for the treatment of the human or non-human

35 mammalian body for treating dementia and/or regression of cognitive function

12

5   comprising telmisartan as ANG II antagonist in an amount of 40 mg to 80 mg and ramipril as ACE inhibitor in an amount of 2.5 mg to 10 mg in single dosage units for simultaneous, separate or sequential use in treatment of said indications, optionally together with one or more pharmaceutically acceptable diluents and/or carriers.

10

9. Use of an ANG II antagonist for manufacture of a pharmaceutical composition according to claim 6 for the treatment of the human or non-human mammalian body for treating the dementia and/or cognitive function when used in combination with an ACE inhibitor.

15

10. Use of telmisartan for manufacture of a pharmaceutical composition according to claim 8 for the treatment of the human or non-human mammalian body for treating dementia and/or regression of cognitive function when used in combination with the ACE inhibitor ramipril.

20